Payment overview · 2025
General Payments
$1,205.70
69 reported records · 18 companies
Healthcare provider profile · identity verified
Timothy R Ivey, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VANCLEAVE, MS · NPI 1902802333
Verified facts
What the public records show
CMS Open Payments records show Timothy R Ivey, M.D. received $1,205.70 in general payments during 2025 across 69 reported records.
ABBVIE INC. accounted for 22.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 193 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 229 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $275.23 | 22.8% | 15 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $188.55 | 15.6% | 12 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $178.76 | 14.8% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.66 | 6.4% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.95 | 6.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $65.52 | 5.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.51 | 4.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.29 | 4.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $46.36 | 3.9% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $34.43 | 2.9% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $33.07 | 2.7% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.05 | 1.9% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $22.16 | 1.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.08 | 1.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.90 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.11 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.69 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.38 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,205.70 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $188.55 | 12 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $178.76 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $157.21 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $157.21 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $118.02 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $71.95 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $65.52 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.51 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $51.29 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $46.36 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $46.17 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $34.43 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $23.05 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 193 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 229 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 183 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
146 | 32 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
193 | 35 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
229 | 55 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
229 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
183 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
100 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
111 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 909 | 184 |
| Amlodipine Besylate | Amlodipine Besylate | 824 | 208 |
| Atorvastatin Calcium | Atorvastatin Calcium | 702 | 198 |
| Gabapentin | Gabapentin | 654 | 177 |
| Pantoprazole Sodium | Pantoprazole Sodium | 592 | 165 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 511 | 135 |
| Losartan Potassium | Losartan Potassium | 444 | 114 |
| Lisinopril | Lisinopril | 422 | 116 |
| Omeprazole | Omeprazole | 370 | 107 |
| Metformin Hcl | Metformin Hcl | 364 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 355 | 103 |
| Duloxetine Hcl | Duloxetine Hcl | 329 | 88 |
| Trazodone Hcl | Trazodone Hcl | 321 | 76 |
| Carvedilol | Carvedilol | 308 | 76 |
| Furosemide | Furosemide | 296 | 80 |
| Montelukast Sodium | Montelukast Sodium | 287 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 277 | 74 |
| Ozempic | Semaglutide | 273 | 50 |
| Citalopram Hbr | Citalopram Hydrobromide | 255 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 233 | 60 |
| Potassium Chloride | Potassium Chloride | 231 | 69 |
| Jardiance | Empagliflozin | 229 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 228 | 89 |
| Prednisone | Prednisone | 211 | 152 |
| Metoprolol Tartrate | Metoprolol Tartrate | 196 | 44 |
| Farxiga | Dapagliflozin Propanediol | 193 | 35 |
| Alprazolam | Alprazolam | 192 | 27 |
| Allopurinol | Allopurinol | 184 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 184 | 42 |
| Mounjaro | Tirzepatide | 183 | 34 |
| Metformin Hcl Er | Metformin Hcl | 172 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 42 |
| Famotidine | Famotidine | 161 | 47 |
| Ezetimibe | Ezetimibe | 157 | 57 |
| Valsartan | Valsartan | 148 | 40 |
| Synthroid | Levothyroxine Sodium | 146 | 32 |
| Glimepiride | Glimepiride | 135 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 53 |
| Donepezil Hcl | Donepezil Hcl | 134 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 134 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 133 | 114 |
| Meloxicam | Meloxicam | 132 | 33 |
| Simvastatin | Simvastatin | 129 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 129 | 38 |
| Celecoxib | Celecoxib | 123 | 45 |
| Lorazepam | Lorazepam | 117 | 22 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 115 | 28 |
| Tramadol Hcl | Tramadol Hcl | 114 | 35 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 113 | 29 |
| Eliquis | Apixaban | 111 | 22 |
| Pregabalin | Pregabalin | 111 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 26 |
| Cefuroxime | Cefuroxime Axetil | 106 | 86 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 27 |
| Alendronate Sodium | Alendronate Sodium | 104 | 30 |
| Bupropion Xl | Bupropion Hcl | 100 | 24 |
| Trulicity | Dulaglutide | 100 | 24 |
| Glipizide | Glipizide | 99 | 28 |
| Levofloxacin | Levofloxacin | 96 | 83 |
| Azelastine Hcl | Azelastine Hcl | 94 | 50 |
| Methylprednisolone | Methylprednisolone | 91 | 77 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 90 | 39 |
| Azithromycin | Azithromycin | 87 | 74 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 85 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 73 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 13 |
| Sertraline Hcl | Sertraline Hcl | 73 | 19 |
| Spironolactone | Spironolactone | 73 | 23 |
| Tresiba Flextouch U-200 | Insulin Degludec | 71 | 18 |
| Buspirone Hcl | Buspirone Hcl | 68 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 68 | 46 |
| Fluconazole | Fluconazole | 67 | 37 |
| Sucralfate | Sucralfate | 66 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 64 | 17 |
| Ibuprofen | Ibuprofen | 63 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 13 |
| Baclofen | Baclofen | 58 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 55 | 27 |
| Estradiol | Estradiol | 55 | 14 |
| Ondansetron Odt | Ondansetron | 55 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 35 |
| Risperidone | Risperidone | 53 | 11 |
| Temazepam | Temazepam | 51 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 49 | suppressed |
| Clonazepam | Clonazepam | 49 | suppressed |
| Amoxicillin | Amoxicillin | 48 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 42 |
| Atenolol | Atenolol | 45 | 15 |
| Clonidine Hcl | Clonidine Hcl | 45 | 18 |
| Novolog Flexpen | Insulin Aspart | 45 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 44 | 14 |
| Finasteride | Finasteride | 44 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 12 |
| Irbesartan | Irbesartan | 43 | 11 |
| Linzess | Linaclotide | 42 | 15 |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Methocarbamol | Methocarbamol | 42 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Rybelsus | Semaglutide | 41 | suppressed |
| Vascepa | Icosapent Ethyl | 41 | suppressed |
| Mirtazapine | Mirtazapine | 40 | 11 |
| Torsemide | Torsemide | 40 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 11 |
| Mupirocin | Mupirocin | 39 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 37 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Ramipril | Ramipril | 36 | 11 |
| Ketoconazole | Ketoconazole | 35 | 13 |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | 11 |
| Nitroglycerin | Nitroglycerin | 34 | suppressed |
| Telmisartan | Telmisartan | 34 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 33 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 23 |
| Meclizine Hcl | Meclizine Hcl | 32 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Valacyclovir | Valacyclovir Hcl | 31 | 16 |
| Novolog | Insulin Aspart | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | 17 |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Repaglinide | Repaglinide | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 19 |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,205.70 · 69 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE, INCEPTIV, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Kerendia, Korlym, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, RECORLEV, REPATHA, REXULTI, TONMYA, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, ZAVZPRET, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error